Drug Trial Radar · NCT06305286
Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)
Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Mar 4, 2024
Primary completion
Mar 2029
Study completion Mar 2029
Sponsor
- Lead sponsor
- University of ChicagoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Juvenile Diabetes Research Foundation; Cure Alliance; Breakthrough T1D; Eledon Pharmaceuticals
- First posted
- Mar 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Tegoprubart (AT-1501) is a monoclonal antibody. Antibodies are Y-shaped proteins that are produced naturally by the subject's immune system to attack and fight foreign substances that cause illness. Monoclonal antibodies are man-made proteins manufactured to serve as substitute antibodies to fight diseases. Monoclonal antibodies can restore, enhance, or mimic (copy) the immune system's attack process; they can also tone down the immune system. Tegoprubart (AT-1501) is thought to work by dampening down the immune system so that it will be less likely to attack the transplanted cells. For other types of transplants, like kidney, a drug called a calcineurin inhibitor is usually used to prevent rejection. That class of drugs can be toxic to islet cells. Tegoprubart (AT-1501) is an experimental agent that is anticipated to prevent rejection without harming the islet cells.
Conditions
- Type 1 Diabetes Mellitus
Interventions
Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapyDrug
Tegoprubart (AT-1501) is a monoclonal antibody for Injection is a humanized immunoglobulin G1 (IgG1) kappa monoclonal anti-CD40L antibody that blocks CD40L binding to its receptor, CD40. Safety and effectiveness of islet transplantation with Tegoprubart- based, calcineurin inhibitor-free (tacrolimus-free) immunosupression regimen is being tested. The goal is improve outcomes of islet transplantation avoiding toxicity and side effect of standard, tacrolimus- based immunosupression therapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants who are insulin-independent post- first and final transplantTime frame: Day 75 and Day 365
- Number of Participants with graft failure post final transplant.Time frame: Day 365
- Number of Participants with glycosylated hemoglobin (HbA1c) <7.0%Time frame: at Day 365
- Number of Participants with free of serious hypoglycemic events (SHEs) post-first and final transplantTime frame: Day 28 to Day 365
- Number of Participants with glycosylated hemoglobin (HbA1c) <6.5%Time frame: Day 28 through to Day 365
- Number of Participants free from SHEs post-first and final transplant.Time frame: Day 28 through to Day 365
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Chicago
Chicago, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.